[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355831-105":59,"doc-detail-355831-en":123},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":116,"head_meta":118,"extra_data":120,"updated_unix":122},105,"en","crip1-functions-as-an-oncogene-in-acute-myeloid-leukemia-by-modulating-glycolytic-metabolic-reprogramming","CRIP1 functions as an oncogene in acute myeloid leukemia by modulating glycolytic metabolic reprogramming","","Acute myeloid leukemia is an aggressive hematologic malignancy with poor outcomes despite current therapies. CRIP1 shows tissue-specific roles, acting as an oncogene in some cancers, but its metabolic connection in AML is insufficiently defined. Lactate release and glucose consumption assays, together with gene expression and Western blot validation after CRIP1 knockdown, assessed glycolytic dependence. CRIP1 depletion reduced AML proliferation and increased sensitivity to the glycolytic inhibitor 2-deoxy-D-glucose.",{"@graph":69,"@context":115},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/crip1-functions-as-an-oncogene-in-acute-myeloid-leukemia-by-modulating-glycolytic-metabolic-reprogramming/355831/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/crip1-functions-as-an-oncogene-in-acute-myeloid-leukemia-by-modulating-glycolytic-metabolic-reprogramming/355831.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109],{"name":110,"@type":111,"acceptedAnswer":112},"Why does 2-deoxy-D-glucose (2-DG) affect CRIP1-deficient AML cells more strongly?","Question",{"text":113,"@type":114},"2-DG inhibits glycolysis and selectively induces marked cell death in CRIP1-deficient cells. The treatment reduced glucose consumption and lactate production, lowering cellular energy availability.","Answer","https://schema.org",{"og:url":83,"og:type":117,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":119,"canonical":83},"index,follow",{"doc_id":121,"site_id":62},355831,1790945371,{"code":4,"msg":5,"data":124},{"doc_id":121,"user_id":125,"nickname":92,"user_avatar":126,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":132,"language":133,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":134,"faqs":135,"seo_title":136,"seo_description":67,"update_tm":137,"read_time":41,"preview_page_count":19,"preview_urls":138},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCRIP1 functions as an oncogene in acute myeloid leukemia by modulating glycolytic metabolic reprogramming  \nMuhammad Asif Zeb1, Aamir Ali Khan2􀀍, Ajaz Ahmad3, Wentao Gui4, Faryal MehwishAwan1, Bhavuk Dhamija5 & Sadiq Noor Khan1􀀍  \nAcute Myeloid leukemia (AML) is a stem cell-derived hematological malignancy associated with rapid progression and poor clinical outcome despite available treatments. CRIP1 exhibits tissue-specific activity, functioning as an oncogene in certain cancers while acting as a tumor suppressor in others. However, the role ofCRIP1 and its association with metabolism inAML remains poorly investigated. To assess its metabolic role, a lactate release and a glucose consumption assay were performed, followed by gene expression analysis of LDHA, MCL1, and HK2 after CRIP1 knockdown. These results were confirmed through Western blot analysis. The CRIP1 knockdown and control cells were treated with 2-DG, a glycolytic inhibitor, and cell death was quantified using flow cytometry. The results showed a significant reduction in the proliferation of AML cells compared to the control, suggesting its oncogenic function. Elevated protein expression of Hexokinase 2, MCL1, and LDHA, suggestsCRIP1’s involvement in regulating the glycolytic pathway. CRIP1 knockdown increased glycolytic dependence, and treatment with 2-deoxy-D-glucose (2-DG) selectively induced marked cell death in CRIP1-deficient cells, demonstrating that loss ofCRIP1 rendersAML cells highly susceptible to glycolytic inhibition. Treatment with 2-DG reduced glucose consumption and lactate production, consequently lowering cellular energy availability and inducing increased cell death. This study reveals a novel role for CRIP1 inAML progression through the modulation of glycolytic biomarkers, highlighting its potential as a therapeutic target.  \nKeywords AML, CRIP1, Metabolism, Glycolytic biomarkers, 2-deoxy-D-glucose (2-DG)  \nAcute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by the clonal expansion of immature myeloid progenitor cells. These aberrant cells infiltrate the bone marrow microenvironment, impairing normal hematopoiesis, leading to reduced production of healthy blood cells1. Malignant transformation in AML arises from acquired genetic mutations, including gain-of-function alterations in proto-oncogenes and loss-of-function mutations in tumor suppressor genes, which collectively drive uncontrolled proliferation and impaired differentiation of the myeloid lineage2. Although AML accounts for only 15–20% of acute leukemia cases, it contributes disproportionately to leukemia-related mortality, representing approximately 30% of deaths, thereby underscoring its significant clinical burden3.  \nCysteine-rich protein 1 (CRIP1) is a member of the LIM/zinc-finger protein family, containing a zincbinding domain that can assist in recruiting or positioning methyltransferase machinery, and is predominantly expressed in intestinal cells, where it contributes to zinc absorption and transport4. Besides its normal function, CRIP1 was found to have aberrant expression in various cancers, including gastric cancer5, colorectal cancer6, pancreatic cancer7, cervical cancer8, and thyroid cancer9, where it functions either as an oncogene or a tumor suppressor, suggesting its tissue-specific role. CRIP1 also plays an important role in regulating vital cancer  \n1Department of Medical Lab Technology, University of Haripur, Haripur 22620, Khyber Pakhtunkhwa, Pakistan.  \n2Department of Medical Lab Technology, Khyber Medical University, Phase 5 Hayatabad, Peshawar 25100, Khyber Pakhtunkhwa, Pakistan. 3Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. 4Department of Cell Biology, Faculty of Science, Charles University, Albertov 6, Prague, Czech Republic. 5Faculty of Medicine, Institute for Clinical Chemistry and L","cbCaibZfgqDAloug","https://ap.wps.com/l/cbCaibZfgqDAloug","pdf",2395831,12,"English","# Abstract\n# Results\n## CRIP1 is preferentially upregulated in AML","[{\"question\":\"Why does 2-deoxy-D-glucose (2-DG) affect CRIP1-deficient AML cells more strongly?\",\"answer\":\"2-DG inhibits glycolysis and selectively induces marked cell death in CRIP1-deficient cells. The treatment reduced glucose consumption and lactate production, lowering cellular energy availability.\"}]","CRIP1 functions as an oncogene in acute myeloid leukemia by modulating glycolytic metabolic reprogramming | PDF",1790121246,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efaa71653cb5ac5e0e087bbeabe6025e.webp",983,1291,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4064bbd856dc2df3a8d66f5e4e33241d.webp",982,1290,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1089ab4730f98c31cb9ae8a46c1ca8e4.webp",981,1289,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a83cb897a010d4d3b4456469596b5bcd.webp",980,1287]